医学
肿瘤科
肺癌
内科学
相伴的
表皮生长因子受体
化疗
酪氨酸激酶抑制剂
酪氨酸激酶
吉非替尼
埃罗替尼
表皮生长因子受体抑制剂
荟萃分析
奥西默替尼
癌症
受体
作者
Thierry Landre,Jean‐Baptiste Assié,Kader Chouahnia,Gaëtan Des Guetz,J.B. Auliac,CHRISTOS CHOUAID
标识
DOI:10.1080/14737140.2024.2362889
摘要
Introduction A tyrosine-kinase inhibitor (TKI) is indicated as a first-line treatment for patients with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor – receptor (EGFR) mutation. Chemotherapy (ChT) given in combination with an EGFR-TKI in this setting is of interest.Methods We conducted a meta-analysis of phase III randomized trials comparing EGFR-TKI + ChT vs. EGFR-TKI alone as first-line therapy for advanced NSCLC harboring an activating EGFR mutation.Results Three studies evaluated gefitinib + ChT (NEJ009, GAP-Brain, and Noronha et al.) and another evaluated osimertinib + ChT (FLAURA-2). Those four eligible studies included 1413 patients with non-squamous NSCLCs, 826 (58%) with an exon-19 deletion (ex19del) and 541 (38%) with EGFRL858R. The EGFR-TKI + ChT combination was significantly associated with prolonged PFS (hazard ratio [HR]: 0.52 [95% confidence interval (CI): 0.45–0.59]; p < 0.0001) and OS (HR: 0.69 [0.52–0.93]; p = 0.01). PFS was particularly improved for patients with brain metastases (HR: 0.41[0.33–0.51]; p < 0.00001).Conclusions For patients with untreated, advanced, EGFR-mutated NSCLCs, the EGFR-TKI + ChT combination, compared to EGFR-TKI alone, was associated with significantly prolonged PFS and OS. However, further studies are needed to identify which patients will benefit the most from the combination.Registration PROSPERO CRD42024508055
科研通智能强力驱动
Strongly Powered by AbleSci AI